LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

LLY

723.01

-3.26%↓

JNJ

146.24

-1.42%↓

UNH

311.66

-2.2%↓

ABBV

179.43

-4.86%↓

ABT

128.75

-0.89%↓

Search

Cogent Biosciences Inc

Chiusa

4.99 -2.54

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

4.79

Massimo

5.15

Metriche Chiave

By Trading Economics

Entrata

-4.1M

-72M

EPS

-0.525

Dipendenti

205

EBITDA

-1.2M

-74M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+222.81% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-50M

584M

Apertura precedente

7.53

Chiusura precedente

4.99

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

13 mag 2025, 23:20 UTC

Utili

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13 mag 2025, 23:48 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13 mag 2025, 23:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

13 mag 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13 mag 2025, 23:24 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

13 mag 2025, 23:24 UTC

Discorsi di Mercato
Utili

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13 mag 2025, 22:58 UTC

Utili

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13 mag 2025, 22:58 UTC

Utili

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13 mag 2025, 22:38 UTC

Utili

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13 mag 2025, 22:38 UTC

Utili

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13 mag 2025, 22:37 UTC

Utili

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13 mag 2025, 22:36 UTC

Utili

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13 mag 2025, 22:35 UTC

Utili

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13 mag 2025, 22:34 UTC

Utili

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13 mag 2025, 22:33 UTC

Utili

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13 mag 2025, 22:30 UTC

Utili

Aristocrat Interim Dividend 44 Australian Cents/Share

13 mag 2025, 22:30 UTC

Utili

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13 mag 2025, 22:29 UTC

Utili

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13 mag 2025, 22:28 UTC

Utili

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13 mag 2025, 21:15 UTC

Utili

Nu Holdings 1Q Rev $3.2B >NU

13 mag 2025, 21:03 UTC

Notizie principali

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

13 mag 2025, 20:32 UTC

Utili

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13 mag 2025, 20:31 UTC

Utili

Alcon 1Q Sales $2.45B >ALC.EB

13 mag 2025, 20:30 UTC

Utili

Alcon 1Q Rev $2.47B >ALC.EB

13 mag 2025, 20:30 UTC

Utili

Alcon 1Q EPS 70c >ALC.EB

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

222.81% in crescita

Previsioni per 12 mesi

Media 16.56 USD  222.81%

Alto 24 USD

Basso 7 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

7

Acquista

3

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Weak Bearish Evidence

A lungo termine

Strong Bearish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.